Altimmune (NASDAQ:ALT – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
78.0% of Altimmune shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 6.2% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Altimmune and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Altimmune | N/A | -31.41% | -26.96% |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Altimmune and TScan Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
Altimmune presently has a consensus price target of $14.33, indicating a potential upside of 562.05%. TScan Therapeutics has a consensus price target of $2.67, indicating a potential upside of 1,128.88%. Given TScan Therapeutics’ higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Altimmune.
Volatility & Risk
Altimmune has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
Earnings & Valuation
This table compares Altimmune and TScan Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Altimmune | $40,000.00 | 10,528.40 | -$88.09 million | ($0.78) | -2.78 |
| TScan Therapeutics | $7.11 million | 2.07 | -$129.77 million | ($0.91) | -0.24 |
Altimmune has higher earnings, but lower revenue than TScan Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Altimmune beats TScan Therapeutics on 8 of the 14 factors compared between the two stocks.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
